HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.

Abstract
Vancomycin is the first-line therapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, but its efficacy in adult patients has been questioned. Less is known about the outcomes of MRSA bacteremia treated with vancomycin in pediatric patients. This study reviews the outcomes and clinical characteristics of MRSA bacteremia in children treated with vancomycin and characterizes the microbiologic and molecular features of the bloodstream isolates. A retrospective cohort study was conducted among pediatric patients with MRSA bacteremia treated with vancomycin for >5 days from 1 August 2005 to 31 May 2007 in a large tertiary care center. MRSA bloodstream isolates were characterized by antimicrobial susceptibility testing, PCR analysis of virulence genes, and Diversilab typing. Clinical records were reviewed for outcomes and comorbidities. A total of 22 pediatric patients with MRSA bacteremia were identified. Eleven cases (50.0%) were considered vancomycin treatment failures. Features significantly associated with vancomycin treatment failure were prematurity (P = 0.02) and isolates positive for Panton-Valentine leukocidin (PVL) (P = 0.008). Features typically associated with community-associated MRSA strains were identified in hospital-associated isolates. A dominant clone was not responsible for the high number of treatment failures. Further studies are needed to determine if vancomycin should be the first-line treatment for MRSA bacteremia in premature infants and for PVL-positive isolates.
AuthorsKerry J Welsh, April N Abbott, Evan M Lewis, Jeanelle M Gardiner, Mark C Kruzel, Cole T Lewis, John F Mohr, Audrey Wanger, Lisa Y Armitige
JournalJournal of clinical microbiology (J Clin Microbiol) Vol. 48 Issue 3 Pg. 894-9 (Mar 2010) ISSN: 1098-660X [Electronic] United States
PMID20089758 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Virulence Factors
  • Vancomycin
Topics
  • Adolescent
  • Anti-Bacterial Agents (therapeutic use)
  • Bacteremia (drug therapy, microbiology, pathology)
  • Bacterial Proteins (genetics)
  • Bacterial Typing Techniques
  • Child
  • Child, Preschool
  • Cohort Studies
  • DNA Fingerprinting
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Methicillin-Resistant Staphylococcus aureus (isolation & purification)
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Staphylococcal Infections (drug therapy, microbiology, pathology)
  • Treatment Outcome
  • Vancomycin (therapeutic use)
  • Virulence Factors (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: